These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 36305696)
1. Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study. Correll CU; Stein E; Graham C; DiPetrillo L; Akerman S; Stanford AD; Jiang Y; Yagoda S; McDonnell D; Hopkinson C Schizophr Bull; 2023 Mar; 49(2):454-463. PubMed ID: 36305696 [TBL] [Abstract][Full Text] [Related]
2. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study. Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605 [No Abstract] [Full Text] [Related]
3. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555 [TBL] [Abstract][Full Text] [Related]
5. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012 [TBL] [Abstract][Full Text] [Related]
7. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. Gao J; Li J; Lu X; Yang J Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507 [TBL] [Abstract][Full Text] [Related]
8. Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. Meyer JM; Simmons A; Jiang Y; Graham C; Yagoda S; McDonnell D CNS Spectr; 2023 Aug; 28(4):478-481. PubMed ID: 36226902 [TBL] [Abstract][Full Text] [Related]
9. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects. Sun L; McDonnell D; Yu M; Kumar V; von Moltke L Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study. Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723 [TBL] [Abstract][Full Text] [Related]
11. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. Toledo FGS; Martin WF; Morrow L; Beysen C; Bajorunas D; Jiang Y; Silverman BL; McDonnell D; Namchuk MN; Newcomer JW; Graham C Neuropsychopharmacology; 2022 Feb; 47(3):696-703. PubMed ID: 34887529 [TBL] [Abstract][Full Text] [Related]
12. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412 [TBL] [Abstract][Full Text] [Related]
14. An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. Citrome L; Graham C; Simmons A; Jiang Y; Todtenkopf MS; Silverman B; DiPetrillo L; Cummings H; Sun L; McDonnell D Neuropsychiatr Dis Treat; 2021; 17():2885-2904. PubMed ID: 34526769 [TBL] [Abstract][Full Text] [Related]
15. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate. Sun L; Yagoda S; Yao B; Graham C; von Moltke L Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140 [TBL] [Abstract][Full Text] [Related]
16. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine. Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206 [TBL] [Abstract][Full Text] [Related]
17. Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder. Pham H; Warlick H; Bermudez R; Nguyen Q; Rey JA J Pharm Technol; 2022 Oct; 38(5):304-313. PubMed ID: 36046346 [TBL] [Abstract][Full Text] [Related]
18. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used? Faden J; Serdenes R; Citrome L Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374 [TBL] [Abstract][Full Text] [Related]
19. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157 [TBL] [Abstract][Full Text] [Related]
20. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]